EVO evotec.com: Indikator likuiditas cepet

Evotec SE (EVO) is attracting leading data experts and biochemists to scale its contract work volume while maintaining a stable headcount. The company is implementing artificial intelligence to accelerate molecule discovery, optimizing partners' laboratory testing costs. This price chart with the 2.19 indicator illustrates the dynamics of a business that generates revenue through long-term R&D agreements and milestone payments from pharmaceutical behemoths.

EVO: Rasio likuiditas perantara Evotec AG 04.07.2022 - 29.10.2026

Ringkesan rincian data analitis evotec.com (EVO)

- rega saham lan prakiraan rega para ahli:

Rega saham Evotec Corp|EVO - Prakiraan konsensus analis

- data kapitalisasi saham perusahaan:

Biji pasar Evotec Corp|EVO - Nilai Dipunlarasaken Utang lan Kas

- indikator kapitalisasi buku:

Nilai Akuntansi saben Saham Evotec|EVO - Total Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku evotec.com|EVO - Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas Evotec SE|EVO - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Evotec|EVO - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Evotec Corp|EVO - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Evotec|Indikator likuiditas cepet evotec.com

- informasi bathi lan kelipatan valuasi:

EVO - Bathi resik perusahaan

Pambiji fundamental perusahaan:Evotec SE

Regular payments from long-term biotech test outsourcing support the solvency of Evotec SE (EVO), creating a stable cash flow. By analyzing a historical snapshot of immediate liquidity, an investor assesses the company's ability to meet its obligations without liquidating inventory, relying solely on cash and accounts receivable, which distinguishes efficient capital management from excessive idle capacity.

Pesaing Evotec SE (EVO)